Management of Chronic Hepatitis B in Treatment-Naive Patients.
- Author:
Jae Youn CHEONG
1
Author Information
1. Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea. jaeyoun620@ajou.ac.kr
- Publication Type:Review ; English Abstract
- Keywords:
Chronic hepatitis B;
Treatment
- MeSH:
Adenine/analogs & derivatives/therapeutic use;
Antiviral Agents/*therapeutic use;
Arabinofuranosyluracil/analogs & derivatives/therapeutic use;
Guanine/analogs & derivatives/therapeutic use;
Hepatitis B, Chronic/*drug therapy;
Humans;
Interferon Alfa-2a/therapeutic use;
Interferon Alfa-2b/therapeutic use;
Korea;
Lamivudine/therapeutic use;
Phosphonic Acids/therapeutic use;
Polyethylene Glycols/therapeutic use;
Practice Guidelines as Topic
- From:The Korean Journal of Gastroenterology
2008;51(6):338-345
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Chronic hepatitis B (CHB) is a serious health problem in Korea. The natural history of chronic HBV infection has been divided into 4 phases: immune tolerance, immune clearance, inactive HBsAg carrier state and reactivation. During the phases of immune tolerance and inactive HBsAg carrier state, no treatment is required. Patients in the immune clearance or reactivation phases are candidates for therapy. In the last years, treatment effects of CHB have considerably improved. Several agents are currently approved for the treatment of CHB: interferon alpha, pegylated interferon alpha, lamivudine, adefovir, entecavir, telbivudine and clevudine in Korea. The treatment recommendations from the 2004 Korean Association for the Study of the Liver guideline on the management of CHB have been updated to incorporate new therapeutic options. What is uncertain is which agent or combination of agents is most effective, how long therapy should last, and which criteria should be used to start, continue, switch or stop therapy. Issues for consideration include efficacy, safety and incidences of resistance, and method of administration of antiviral therapy in treatment-naive patients.
